- Home
- BY vs JANX Comparison
BY vs JANX Comparison
Compare BY & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- JANX
- Stock Information
- Founded
- BY 1914
- JANX 2017
- Country
- BY United States
- JANX United States
- Employees
- BY N/A
- JANX N/A
- Industry
- BY Major Banks
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- JANX Health Care
- Exchange
- BY Nasdaq
- JANX Nasdaq
- Market Cap
- BY 1.2B
- JANX 1.4B
- IPO Year
- BY 2017
- JANX 2021
- Fundamental
- Price
- BY $28.38
- JANX $24.88
- Analyst Decision
- BY Hold
- JANX Strong Buy
- Analyst Count
- BY 3
- JANX 7
- Target Price
- BY $33.67
- JANX $94.29
- AVG Volume (30 Days)
- BY 363.3K
- JANX 658.5K
- Earning Date
- BY 07-24-2025
- JANX 08-06-2025
- Dividend Yield
- BY 1.41%
- JANX N/A
- EPS Growth
- BY N/A
- JANX N/A
- EPS
- BY 2.69
- JANX N/A
- Revenue
- BY $379,386,000.00
- JANX $9,336,000.00
- Revenue This Year
- BY $16.23
- JANX N/A
- Revenue Next Year
- BY $3.79
- JANX $1,470.82
- P/E Ratio
- BY $10.55
- JANX N/A
- Revenue Growth
- BY 3.48
- JANX 28.12
- 52 Week Low
- BY $22.63
- JANX $22.48
- 52 Week High
- BY $32.89
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- BY 72.32
- JANX 50.75
- Support Level
- BY $26.54
- JANX $22.74
- Resistance Level
- BY $26.03
- JANX $24.73
- Average True Range (ATR)
- BY 0.53
- JANX 1.25
- MACD
- BY 0.32
- JANX 0.16
- Stochastic Oscillator
- BY 96.49
- JANX 60.44
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.